# KEYNOTE-B49 (NCT04895358)

> Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04895358
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Breast Neoplasms
- Interventions: pembrolizumab; paclitaxel; nab-paclitaxel; liposomal doxorubicin; capecitabine; normal saline; dextrose
- Enrollment: 342
- Primary outcome: Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) by Blinded Independent Central Review (BICR) in Participants With Combined Positive Score (CPS) ≥1

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 8

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=keynote-b49-nct04895358

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04895358", "email": "<work email>"}; the inbox owner confirms by the emailed link.